Asthma treatment: 'magic bullets which seek their own targets'.
The most fascinating options of the new asthma treatments are probably represented by monoclonal antibodies. In fact, these molecules are virtually able to interact with whatever specific antigen. Anyway, it is mandatory to understand the limits of this group of molecules, in terms of both efficacy and safety. In this review, we have analyzed different ways of interfering along the course of the cascade of the allergic reaction, targeting different molecules (CD4, TNF-alpha, IL-4, IL-5, IL-10, IL-12, endothelial adhesion molecules, IgE), showing the efficacy and the risks of each kind of treatment. In the end, we focused our attention on omalizumab, the monoclonal antibody targeting IgE. Although with some restrictions, represented by the high costs and the limitation of its use only to a specific subset of patients affected by allergic asthma, at present anti-IgE appear to be the only 'magic bullet' for the treatment of allergic asthma. In fact, it proved to reduce exacerbations and symptom scores, and to improve quality of life, with a very good safety profile.
Tarantini
F
F
Allergy and Respiratory Diseases, DIMI--University of Genoa, Genova, Italy.
Baiardini
I
I
Passalacqua
G
G
Braido
F
F
Canonica
G W
GW
D018927:Anti-Asthmatic Agents / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D000069444:Omalizumab; D011788:Quality of Life
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E